Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3954MR)

This product GTTS-WQ3954MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3954MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6389MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ2555MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ2047MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ10529MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ13204MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ4513MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ6436MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ5860MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW